LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
2.71 USD -4.24% Intraday chart for LAVA Therapeutics N.V. -13.42% +71.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 CI
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Slipping Thursday Afternoon MT
Sector Update: Health Care MT
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer MT
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures MT
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda DJ
Top Premarket Gainers MT
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA CI
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Adjusts Price Target on Lava Therapeutics to $6 From $9, Maintains Buy Rating MT
LAVA Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Lava Therapeutics to Halt LAVA-051 Clinical Trial, Focus on Potential Prostate Cancer Treatment LAVA-1207 MT
LAVA Therapeutics N.V. Provides Updates on Clinical Programs and Extends the Cash Runway CI
LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sector Update: Health Care Stocks Rising Late Friday MT
Sector Update: Health Care MT
Top Midday Gainers MT
Top Premarket Gainers MT
LAVA Therapeutics Shares Rise Premarket Following Selection by Janssen Biotech to Support Development of Cancer Treatment MT
North American Morning Briefing : Stock Futures Rise as Jobs Report Swings Into Focus DJ
Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus DJ
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Chart LAVA Therapeutics N.V.
More charts
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.541 EUR
Average target price
6.684 EUR
Spread / Average Target
+163.08%
Consensus